Efficacy and Tolerability of a Fixed-Dose Benzoyl Peroxide 5% and Clindamycin 1% Gel Alone or in Combination with Oral Vitamin A 50.000 IU in the Treatment of Mild-to-Moderate Acne: A Prospective, Randomized, Assessor Blinded Trial
Introduction & Objectives: Benzoyl peroxide (BPO) is commonly used alone or in combination with retinoids or antibiotics as first line treatment in acne vulgaris (AV).BPO-based topical anti-AV products are effective however, often, the skin tolerability profile is not optimal due to skin irritation and skin dryness commonly observed during treatment.It is frequently needed to combine an appropriate dermo cosmetic approach to restore the function of the skin barrier.The fixed-dose combination of BPO with clindamycin (BPO-Cli) has demonstrated to be very effective and well tolerated in the treatment of AV.Oral vitamin A (retinol) has shown to improve AV lesions mainly in non-controlled observational studies with a good skin tolerability.Some data suggest that oral Vitamin A could also have beneficial effects on gut microbiome.So far, no controlled data regarding an "In&Out" strategy using BPO-Cli topical product and oral Vitamin A have been conducted in AV treatment.We evaluated and compared the efficacy and tolerability of BPO-Cli gel alone or in combination with oral Vitamin A in subjects with mildto-moderate AV.In addition, as secondary endpoint, we evaluated the effect of combination therapy on gut microbiome by mean of Trimethylamine N-Oxide (TMAO) serum measurements.Materials & Methods: In a randomised, prospective, assessor-blinded trial a total of sixty subjects (10 men and 50 women, mean age: 24 years) with AV were enrolled in an 8-week trial, after their informed written consent.Thirty subjects were allocated to BPO-Cli gel treatment (one application per day in the morning) (Group A) and thirty subjects were allocated to BPO-Cli gel and Vitamin A oral supplementation (50.000IU) once daily (Group B).The primary endpoint was the evolution of Global Acne Grading System (GAGS) assessing AV lesions number and type (with a score of 0 representing no lesions, 1-18 mild, 19-30 moderate, and >31 severe and very severe acne).GAGS score was evaluated at baseline and after 8 weeks by an investigator unaware of treatment allocation.As indirect parameter of gut microbiota we also measured serum TMAO level in group B subjects at baseline and after treatment.Results: All subjects concluded the 8-week treatment period.No severe adverse events were registered in both groups.At baseline the GAGS score was 26.23.0 in Group A and 25.92.6 in Group B. After 8-week of treatment Group A shown a percentage reduction of GAGS in comparison with baseline values of -40%.In the Group B the percentage reduction was -www.yumedtext.com
Authors
- Giuseppina Caiazzo (ORCID: https://orcid.org/0000-0003-0274-5308)
- Fabrizio Martora (ORCID: https://orcid.org/0000-0003-2523-050X)
- Massimo Milani (ORCID: https://orcid.org/0000-0001-7559-1202)
- Maria Carmela Annunziata (ORCID: https://orcid.org/0000-0002-6498-565X)
- Francesca Colombo (ORCID: https://orcid.org/0000-0002-8099-0192)
Publication Details
- Journal
- Archives of Clinical & Experimental Dermatology
- Published
- 2024-12-27
- DOI
- https://doi.org/10.46527/2583-6374.159
- Primary Topic
- Acne and Rosacea Treatments and Effects
- Type
- article
- Field-Weighted Citation Impact
- 0.00